Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license ... Read More